ロード中...
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
BACKGROUND: Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However, in comparison with widely adopted mono-immune checkpoint inhibitors, chemothe...
保存先:
| 出版年: | Exp Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6815037/ https://ncbi.nlm.nih.gov/pubmed/31673481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0150-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|